Torrent Pharmaceuticals has announced the successful completion of a USFDA inspection at its manufacturing facility located in Visakhapatnam, Andhra Pradesh.
The inspection was conducted between July 28 and August 1, 2025, as part of the routine regulatory oversight by the United States Food and Drug Administration. Importantly, the inspection concluded with zero observations, meaning no Form 483 was issued — a strong indicator of the company’s high standards in manufacturing and compliance.
This positive outcome highlights Torrent Pharma’s robust quality systems and adherence to international regulatory requirements. It also reinforces the company’s commitment to maintaining global best practices in its operations.
In the meantime, Torrent Pharmaceuticals shares ended lower on Friday, settling at ₹3,660.10, down by 2.19% from the previous close. The stock opened the day at ₹3,740.90, which also marked its highest point during the session. However, it slipped during the day to hit a low of ₹3,642.00 before closing near that level. The company’s stock has shown strength over the past year, with a 52-week high of ₹3,787.90 and a 52-week low of ₹2,886.45
